Teva Surges 7% With Q3 Results Three Days Away

TEVA closed at $42.09 on Friday, up 7% on the week, and the options market is leaning harder into the upside than at almost any point in the past year.

The put/call ratio finished at 0.49 on Thursday, more than one standard deviation below its 20-day average of 0.52 and near the bottom of its 52-week range of 0.44 to 0.59. Call-side positioning has been building steadily as the stock climbed, with the ratio drifting lower through October from readings above 0.55 in late September. That kind of one-directional options flow, call-heavy into a known catalyst, reflects a market that has largely pre-positioned for a constructive Q3 print on November 3.

The lending market offers no counterweight to that optimism. Borrow availability is around 1,293% of short interest, meaning there are well over a dozen shares available for every one currently shorted, and cost to borrow is a low 0.52%. Both figures are consistent with a stock where short sellers have been quietly reducing exposure rather than adding. Estimated short interest slipped about 0.7% over the past week and has retreated from a local peak above 36 million shares in early October to roughly 30 million. The ORTEX short score of 42.6 is mid-range and has eased from a recent high near 44 in mid-October. None of this reads as a crowded short or a developing squeeze. It reads as a lend market with plenty of supply and diminishing demand.

The valuation picture carries some internal tension. At roughly 14x trailing earnings and 11.6x EV/EBITDA, Teva is not expensive for a generics-and-specialty pharmaceutical company showing momentum. Both multiples have expanded over the past 30 days as the stock has run. The earnings yield factor ranks in the 85th percentile of the universe, a genuine value signal, while the ORTEX momentum pillar sat at 92.6 out of 100 as of late September, driven by 52-week price highs and relative strength across multiple timeframes. BlackRock added aggressively to its position, raising its stake to 8.4% of shares in the most recent quarter, a material addition of nearly 28 million shares. WCM Investment Management and State Street also added in the same period. The institutional base has been building into strength rather than trimming.

The one piece of history worth carrying into the November 3 print: the July 29 Q2 results produced a one-day move of just over 30%. With the stock already up roughly 7% in the week before Q3 results, the bar for a repeat of that reaction is considerably higher, and the positioning tells you the market knows it.

The specific number to watch before Monday's open is the Q3 revenue figure against consensus. With multiples already expanded and momentum priced in, guidance tone will matter more than the beat-or-miss on earnings per share.